

Assessment of the value of hyoscine butylbromide (Buscopan®) in optimising image quality for patients undergoing pelvic magnetic resonance imaging

Submission date 30/09/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/09/2004	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/04/2012	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr B Taylor

Contact details
X-Ray Diagnostic
Christie Hospital NHS Trust
Wimslow Road
Withington
Manchester
United Kingdom
M20 4BX

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0063139427

Study information

Scientific Title

Study objectives

To determine whether intravenous hyoscine butylbromide (Buscopan®) results in a significant improvement in magnetic resonance (MR) image quality and improves diagnostic accuracy, thereby benefitting patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

A cohort observation, randomised single-blinded trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Screening

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Magnetic resonance imaging (MRI)

Interventions

Before pelvic magnetic resonance imaging patient will received either intravenous hyoscine butylbromide or a placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Hyoscine butylbromide (Buscopan®)

Primary outcome measure

Overall image quality and visualisation of individual pelvic structures and visualisation of tumours on MR images, both with and without Buscopan®.

Secondary outcome measures

Not provided at time of registration

Overall study start date

20/01/2004

Completion date

31/12/2008

Eligibility

Key inclusion criteria

Patients undergoing pelvic magnetic resonance imaging.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

20/01/2004

Date of final enrolment

31/12/2008

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
X-Ray Diagnostic
Manchester
United Kingdom
M20 4BX

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type
Government

Funder Name
Christie Hospital NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2007		Yes	No